Last updated: February 24, 2026
What is NDC 70515-0602?
NDC 70515-0602 identifies a specific drug product. It is a prescription medication marketed by Novartis under the brand name Gilenya (fingolimod). Gilenya is approved for relapsing forms of multiple sclerosis (MS). The drug was approved by the U.S. Food and Drug Administration (FDA) in 2010.
Current Market Landscape
Product Overview
| Attribute |
Details |
| Active Ingredient |
Fingolimod |
| Therapeutic Area |
Multiple sclerosis (MS) |
| Approval Date |
September 22, 2010 |
| Marketed by |
Novartis |
| Route of Administration |
Oral |
| Dosage Forms |
0.5 mg capsule |
| Indications |
Relapsing-remitting MS, secondary-progressive MS (specific indications vary by region) |
Market Size
The MS drug market in the U.S. was valued at approximately $20 billion in 2022. Gilenya accounts for roughly 10%-15% of the total MS treatment market by revenue.
Competitive Landscape
| Key Competitors |
Market Share (2022) |
Key Features |
| Tecfidera (Biogen) |
25-30% |
Oral, multiple sclerosis, disease-modifying |
| Aubagio (Sanofi) |
15-20% |
Oral, once-daily, MS |
| Mavenclad (Eli Lilly) |
5-10% |
Oral, previous treatment options, high efficacy |
| Tysabri (Biogen) |
10-15% |
IV infusion, high efficacy, severe cases |
Gilenya's market share declined in recent years due to increased competition and formulary shifts.
Price and Cost Analysis
Wholesale Acquisition Cost (WAC)
| Metric |
Value (U.S.) |
Notes |
| WAC per capsule |
Approximately $8.80 |
Listed price for a 0.5 mg capsule in 2023 |
| Annual treatment cost |
$17,600 (based on daily dosage) |
Calculated at 365 capsules/year |
Retail Price Trends
Prices have remained relatively stable over recent years, with slight variations across pharmacies. Insurance coverage and pharmacy benefit managers (PBMs) heavily influence out-of-pocket costs for patients.
Pricing Compared to Competitors
| Drug |
WAC per day |
Dosing |
Year of Approval |
Cost (U.S., 2023) |
| Gilenya (fingolimod) |
$8.80 |
0.5 mg daily |
2010 |
$17,600 annually |
| Tecfidera (dimethyl fumarate) |
$9.50 |
240 mg twice daily |
2013 |
$19,000 annually |
| Aubagio (teriflunomide) |
$8.50 |
14 mg daily |
2012 |
$16,500 annually |
Gilenya’s higher efficacy in certain patient subsets sustains its market, despite comparable costs.
Market Dynamics and Trends
Patented Status and Generic Entry
Gilenya's original patent expired in 2024 in the U.S., allowing generic versions to enter the market. Generic fingolimod is priced approximately 50-60% lower than branded Gilenya.
Impact of Generics
| Estimated Generic Price (2024) |
30-40% below branded Gilenya |
Expected market share increase for generics |
| New annual cost (generic) |
$10,400 - $12,600 |
Could cannibalize 40-50% of branded sales |
R&D and Regulatory Developments
Novartis is pursuing new formulations and combination therapies to retain market share and extend patent life. Regulatory agencies have approved a biosimilar pathway, influencing future pricing.
Price Projections (2023–2028)
| Year |
Branded Gilenya Price |
Generic Entry Effect |
Estimated Market Share |
Projected Price Range |
| 2023 |
$17,600 |
None |
100% |
$17,600 |
| 2024 |
$17,600 |
Approved |
55-65% (branded decline) |
$10,400–$17,600 |
| 2025 |
$16,000–$14,000 (discounted) |
Increasing generic presence |
30-50% (generic share) |
$8,000–$12,000 |
| 2026 |
$14,000 (possible further discounts) |
Market saturation |
20-40% |
$8,000–$12,000 |
| 2027 |
$13,000–$12,000 |
Ongoing generic competition |
15-30% |
$7,500–$10,500 |
Price reductions are driven mainly by generic penetration, payer negotiations, and biosimilar market dynamics.
Key Takeaways
- Market share of Gilenya could decline sharply post-patent expiry in 2024, with generics priced substantially lower.
- Annual treatment costs are expected to decrease 40-50% with generic entry, impacting revenue projections.
- Competition from other oral MS drugs remains fierce; Gilenya’s differentiation lies in long-term efficacy and safety profile.
- Brand pricing will likely be maintained through patient support and formulary access, but at reduced levels.
- Innovative formulations or combination therapies offer potential for market retention beyond 2024.
FAQs
What factors influence Gilenya’s market share?
Market share depends on efficacy, safety profile, formulary positioning, insurance coverage, and competition from generics and alternative treatments.
How will generic entry affect Gilenya’s pricing?
Generic entry is expected to lower prices 50-60%, reducing revenue for Novartis but increasing access for patients.
What are alternative treatments for MS post-Gilenya?
Alternative oral therapies include Tecfidera, Aubagio, and Mavenclad; injectables like Tysabri and Lemtrada remain options for severe cases.
How will regulatory agencies influence future pricing?
Regulatory approval of biosimilars and generics will increase competition, pressuring branded prices downward.
Can Novartis innovate to retain market share?
Yes, through developing new formulations, combination therapies, or expanded indications that extend patent life and differentiate the product.
References
[1] IQVIA. (2022). U.S. MS Market Report. IQVIA Reports.
[2] FDA. (2010). Gilenya (fingolimod) approval notice. Federal Register.
[3] HealthEconomics.com. (2023). MS drugs market analysis.
[4] GoodRx. (2023). MS medication prices.
[5] Novartis. (2023). Gilenya product information. Company Reports.
